Antipsychotics with inverse agonist activity at the dopamine D3 receptor

Journal of Neural Transmission

Volumn 103, Issue 10, 1996, Pages 1163-1175

  Griffon, N ^a,b   Pilon, C ^a   Sautel, F ^a   Schwartz, J C ^a   Sokoloff, P ^a  

^a INSERM   (France)

^b CENTRE PAUL BROCA   (France)

Author keywords

3H thymidine incorporation; Cyclic AMP accumulation; Negative antagonist; Partial agonist

Indexed keywords

5 METHOXY 1 METHYL 2 PROPYLAMINOTETRALIN; CHLORPROMAZINE; CYCLIC AMP; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ETICLOPRIDE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERTUSSIS TOXIN; PIMOZIDE; PROCHLORPERAZINE; RACLOPRIDE; RISPERIDONE; SULPIRIDE; THIOPROPERAZINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG POTENCY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; CALCIUM; CHO CELLS; CLOZAPINE; CRICETINAE; CYCLIC AMP; DNA REPLICATION; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUPENTHIXOL; FORSKOLIN; GLIOMA; HALOPERIDOL; HUMANS; HYBRID CELLS; NAPHTHALENES; NEUROBLASTOMA; PERTUSSIS TOXIN; PHENOTHIAZINES; PIMOZIDE; PYRROLIDINES; QUINPIROLE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECOMBINANT PROTEINS; RISPERIDONE; SALICYLAMIDES; SECOND MESSENGER SYSTEMS; SULPIRIDE; TETRAHYDRONAPHTHALENES; TUMOR CELLS, CULTURED; VIRULENCE FACTORS, BORDETELLA;

EID: 0029824606     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01271201     Document Type: Article

References (38)

1. 2 adrenoceptor: evidence for empty receptor stimulation of the adenylate cyclase cascade. Biochem J 303: 803-808
2. Barker EL, Westphal RS, Schmidt D, Sanders-Bush E (1994) Constitutively active 5-hydroxytryptamine 2c receptors reveal novel inverse agonist activity of receptors ligands. J Biol Chem 269: 11687-11690
3. 2-adrenoreceptor. Nature 374: 272-276
4. Boone C, Davis NG, Sprague GF (1993) Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype. Proc Natl Acad Sci USA 90: 9921-9925
5. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M (1994) Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45: 490-499
6. 2 dopamine receptors. Mol Pharmacol 45: 51-60
7. Costa TH, Herz A (1989) Antagonists with negative intrinsic activity at opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86: 7321-7325
8. Costa T, Ogino Y, Munson PJ, Oranan HO, Rodbard D (1992) Drug efficacy at guanine nucleotide-binding regulatory protein linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 41: 549-560
9. 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc Natl Acad Sci USA 87: 2896-2900
10. DeLean A, Stadel JM, Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 255: 7108-7117
11. 3 receptor. Neuroscience 65: 731-745
12. Duprez L, Parma J, Van Sande J, Allgeier A, Leclère J, Schvartz C, Deliste MJ, Decoulx M, Orgiazzi J, Dunont J, Vassart G (1994) Germline mutations in the tyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nature Genet 7: 396-401
13. 3 dopamine receptor. J Pharmacol Exp Ther 268: 417-426
14. 3 receptor ligand (+)UH 232 is a partial agonist. Eur J Pharmacol 282: R3-R4
15. 3 receptor. Biochem Soc Trans 24: 193-198
16. 3 receptors are elevated in mesolimbic dopamine system of schizophrenics: receptor autoradiographic studies. Neuropsychopharmacol 10: 236S
17. 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267: 1430-1433
18. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16: 89-97
19. 3 receptor expressed in transfected cell lines. Eur J Pharmacol Mol Pharmacol Sect 266: 79-85
20. Milligan G, Bond RA, Lee M (1995) Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 16: 10-13
21. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dunont J, Vassart G (1993) Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365: 649-651
22. 3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur J Pharmacol [Mol Pharmacol Sect] 268: 129-139
23. Rao RV, Cohen GB, Oprian DD (1994) Rhodopsin mutation G90D and a molecular mechanism for congenital right blindness. Nature 367: 639-642
24. Ren Q, Kurose H, Lefkowitz RJ, Cotecchia S (1993) Constitutively active mutants of the alpha-2-adrenergic receptor. J Biol Chem 268: 16483-16487
25. Robbins LS, Nadeau JH, Johnson KR, Kelly MA, Roselli-Rehfuss L, Baaek E, Mountjoy KG, Cone RD (1993) Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72: 827-834
26. Robinson PR, Cohen GB, Zhukovsky EA, Oprian DD (1992) Constitutively active mutants of rhodopsin. Neuron 9: 719-725
27. 2-adrenergic receptor. J Biol Chem 268: 4625-4636
28. 2-adrenergic receptor. Mol Pharmacol 45: 390-394
29. 2 receptors. NeuroReport 6: 329-332
30. 3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 275: 1239-1246
31. 1 pituitary cells. FEBS Lett 312: 123-126
32. Shenker A, Lane L, Kosugi S, Merendino JJ, Minegishi T, Cutler GB (1993) A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365: 652-654
33. Sokoloff P, Schwartz JC (1995) The novel dopamine receptors half a decade later. Trends Pharmacol Sci 16: 270-275
34. 3) as a target for neuroleptics. Nature 347: 146-151
35. 2 receptor. Eur J Pharmacol Mol Pharmacol Sect 225: 331-337
36. 3 receptors. Eur J Pharmacol 263: 235-243
37. 4 dopamine receptors in fibroblasts and dopaminergic cell lines. J Pharmacol Exp Ther 268: 495-502
38. 1B receptor subtype. J Biol Chem 269: 27925-27931